.png){kind=icon}
.png){kind=icon}
Return
From synaptic development to degeneration: a narrative review of small molecule strategies targeting alpha-synuclein in Parkinson’s disease
.png){kind=icon}
PRE
AI
L
K
C
Y
J
Y
M
S
DOI：10.1007/s11011-026-01911-y.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Aggregation of α-synuclein (α-Syn) is a defining pathological feature of Parkinson’s disease (PD), contributing to progressive neuronal dysfunction and death. Unlike prior reviews focused predominantly on aggregation as an isolated endpoint, this review proposes a neurodevelopmental–neurodegenerative continuum as an interpretive framework, suggesting that α-Syn’s physiological roles in synaptic development and circuit maturation may be linked to its later pathological behaviour. Within this context, we discuss recent advances in small-molecule strategies targeting key stages of α-Syn pathology, including synthesis, misfolding, aggregation, post-translational modification, and clearance. These include translation and misfolding inhibitors, aggregation modulators such as minzasolmin (UCB0599), epigallocatechin gallate and anle138b, as well as compounds that enhance α-Syn degradation through autophagy–lysosomal and ubiquitin–proteasome pathways. Additional strategies targeting proteostasis and mitochondrial dysfunction are also considered. Beyond its pathogenic role, α-Syn contributes to synaptic vesicle trafficking, neurotransmitter release, and neuronal maturation, and disruption of these functions may increase vulnerability to later neurodegeneration. In conclusion, small-molecule-based therapies represent a promising multi-targeted strategy for PD; however, key translational challenges and unresolved questions remain, including optimisation of pharmacokinetics, target specificity, and blood-brain barrier (BBB) penetration and validation in clinical settings.
Keywords:
Alpha-synuclein
Parkinson’s disease
Small molecules
Post-translational modifications
Journal
IF:
3.5
Papers:
3.2K
Citations:
6.3K
Organization
Cited Papers